FACTBOX-Developers of potential Ebola vaccines and treatments

Mon Aug 11, 2014 2:28pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

Aug 11 (Reuters) - Several companies with potential Ebola vaccines and treatments have captured the spotlight, as developers face mounting pressure to expedite research on new medical interventions.

The Ebola epidemic in West Africa has killed nearly 1,000 people and prompted the World Health Organization to declare an international health emergency.

No Ebola drugs or vaccines have entered mid-stage human trials, let alone been approved. The most advanced have been tested only in monkeys and a handful of humans.

VACCINES

GLAXOSMITHKLINE PLC

GSK is co-developing a vaccine with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), which has shown promising results in primates.

The vaccine is due to enter early-stage human trials, pending U.S. Food and Drug Administration approval. GSK has said human testing should start this year. NIAID expects trials to begin "as early as fall 2014."

Even if it is fast-tracked and works as well as hoped, the new vaccine could not be ready for widespread deployment before 2015.   Continued...